231 related articles for article (PubMed ID: 27862236)
1. Allogeneic major histocompatibility complex-mismatched equine bone marrow-derived mesenchymal stem cells are targeted for death by cytotoxic anti-major histocompatibility complex antibodies.
Berglund AK; Schnabel LV
Equine Vet J; 2017 Jul; 49(4):539-544. PubMed ID: 27862236
[TBL] [Abstract][Full Text] [Related]
2. Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo.
Pezzanite LM; Fortier LA; Antczak DF; Cassano JM; Brosnahan MM; Miller D; Schnabel LV
Stem Cell Res Ther; 2015 Apr; 6(1):54. PubMed ID: 25889095
[TBL] [Abstract][Full Text] [Related]
3. Allo-antibody production after intraarticular administration of mesenchymal stem cells (MSCs) in an equine osteoarthritis model: effect of repeated administration, MSC inflammatory stimulation, and equine leukocyte antigen (ELA) compatibility.
Barrachina L; Cequier A; Romero A; Vitoria A; Zaragoza P; Vázquez FJ; Rodellar C
Stem Cell Res Ther; 2020 Feb; 11(1):52. PubMed ID: 32028995
[TBL] [Abstract][Full Text] [Related]
4. Equine bone marrow-derived mesenchymal stromal cells are heterogeneous in MHC class II expression and capable of inciting an immune response in vitro.
Schnabel LV; Pezzanite LM; Antczak DF; Felippe MJ; Fortier LA
Stem Cell Res Ther; 2014 Jan; 5(1):13. PubMed ID: 24461709
[TBL] [Abstract][Full Text] [Related]
5. Immune response to allogeneic equine mesenchymal stromal cells.
Kamm JL; Riley CB; Parlane NA; Gee EK; McIlwraith CW
Stem Cell Res Ther; 2021 Nov; 12(1):570. PubMed ID: 34772445
[TBL] [Abstract][Full Text] [Related]
6. Donor-derived equine mesenchymal stem cells suppress proliferation of mismatched lymphocytes.
Ranera B; Antczak D; Miller D; Doroshenkova T; Ryan A; McIlwraith CW; Barry F
Equine Vet J; 2016 Mar; 48(2):253-60. PubMed ID: 25582202
[TBL] [Abstract][Full Text] [Related]
7. Transforming Growth Factor-β2 Downregulates Major Histocompatibility Complex (MHC) I and MHC II Surface Expression on Equine Bone Marrow-Derived Mesenchymal Stem Cells Without Altering Other Phenotypic Cell Surface Markers.
Berglund AK; Fisher MB; Cameron KA; Poole EJ; Schnabel LV
Front Vet Sci; 2017; 4():84. PubMed ID: 28660198
[TBL] [Abstract][Full Text] [Related]
8. Cross-matching of allogeneic mesenchymal stromal cells eliminates recipient immune targeting.
Rowland AL; Miller D; Berglund A; Schnabel LV; Levine GJ; Antczak DF; Watts AE
Stem Cells Transl Med; 2021 May; 10(5):694-710. PubMed ID: 33369287
[TBL] [Abstract][Full Text] [Related]
9. Blood type and breed-associated differences in cell marker expression on equine bone marrow-derived mesenchymal stem cells including major histocompatibility complex class II antigen expression.
Kamm JL; Parlane NA; Riley CB; Gee EK; Dittmer KE; McIlwraith CW
PLoS One; 2019; 14(11):e0225161. PubMed ID: 31747418
[TBL] [Abstract][Full Text] [Related]
10. Immunoprivileged no more: measuring the immunogenicity of allogeneic adult mesenchymal stem cells.
Berglund AK; Fortier LA; Antczak DF; Schnabel LV
Stem Cell Res Ther; 2017 Dec; 8(1):288. PubMed ID: 29273086
[TBL] [Abstract][Full Text] [Related]
11. The immunomodulation-immunogenicity balance of equine Mesenchymal Stem Cells (MSCs) is differentially affected by the immune cell response depending on inflammatory licensing and major histocompatibility complex (MHC) compatibility.
Cequier A; Vázquez FJ; Romero A; Vitoria A; Bernad E; García-Martínez M; Gascón I; Barrachina L; Rodellar C
Front Vet Sci; 2022; 9():957153. PubMed ID: 36337202
[TBL] [Abstract][Full Text] [Related]
12. Production of Cytotoxic Antibodies After Intra-Articular Injection of Allogeneic Synovial Membrane Mesenchymal Stem Cells With and Without LPS Administration.
Rosa GDS; Krieck AMT; Padula ET; Stievani FC; Rossi MC; Pfeifer JPH; Basso RM; Braz AMM; Golim MA; Alves ALG
Front Immunol; 2022; 13():871216. PubMed ID: 35572507
[TBL] [Abstract][Full Text] [Related]
13. Histocompatibility testing of cultivated human bone marrow stromal cells - a promising step towards pre-clinical screening for allogeneic stem cell therapy.
Koppula PR; Chelluri LK; Polisetti N; Vemuganti GK
Cell Immunol; 2009; 259(1):61-5. PubMed ID: 19577229
[TBL] [Abstract][Full Text] [Related]
14. Multiple intravenous injections of allogeneic equine mesenchymal stem cells do not induce a systemic inflammatory response but do alter lymphocyte subsets in healthy horses.
Kol A; Wood JA; Carrade Holt DD; Gillette JA; Bohannon-Worsley LK; Puchalski SM; Walker NJ; Clark KC; Watson JL; Borjesson DL
Stem Cell Res Ther; 2015 Apr; 6(1):73. PubMed ID: 25888916
[TBL] [Abstract][Full Text] [Related]
15. Retrospective analysis of local injection site adverse reactions associated with 230 allogenic administrations of bone marrow-derived mesenchymal stem cells in 164 horses.
Ursini TL; Amelse LL; Elkhenany HA; Odoi A; Carter-Arnold JL; Adair HS; Dhar MS
Equine Vet J; 2019 Mar; 51(2):198-205. PubMed ID: 29992618
[TBL] [Abstract][Full Text] [Related]
16. TGF-β2 Reduces the Cell-Mediated Immunogenicity of Equine MHC-Mismatched Bone Marrow-Derived Mesenchymal Stem Cells Without Altering Immunomodulatory Properties.
Berglund AK; Long JM; Robertson JB; Schnabel LV
Front Cell Dev Biol; 2021; 9():628382. PubMed ID: 33614658
[TBL] [Abstract][Full Text] [Related]
17. Effect of allogeneic platelet lysate on equine bone marrow derived mesenchymal stem cell characteristics, including immunogenic and immunomodulatory gene expression profile.
Yaneselli K; Barrachina L; Remacha AR; Algorta A; Vitoria A; Cequier A; Romero A; Vázquez FJ; Maisonnave J; Rodellar C
Vet Immunol Immunopathol; 2019 Nov; 217():109944. PubMed ID: 31563725
[TBL] [Abstract][Full Text] [Related]
18. Preferential expansion of human umbilical cord blood-derived CD34-positive cells on major histocompatibility complex-matched amnion-derived mesenchymal stem cells.
Mizokami T; Hisha H; Okazaki S; Takaki T; Wang XL; Song CY; Li Q; Kato J; Hosaka N; Inaba M; Kanzaki H; Ikehara S
Haematologica; 2009 May; 94(5):618-28. PubMed ID: 19336739
[TBL] [Abstract][Full Text] [Related]
19. Polymorphism at expressed DQ and DR loci in five common equine MHC haplotypes.
Miller D; Tallmadge RL; Binns M; Zhu B; Mohamoud YA; Ahmed A; Brooks SA; Antczak DF
Immunogenetics; 2017 Mar; 69(3):145-156. PubMed ID: 27889800
[TBL] [Abstract][Full Text] [Related]
20. Cell-dose-dependent increases in circulating levels of immune effector cells in rhesus macaques following intracranial injection of allogeneic MSCs.
Isakova IA; Dufour J; Lanclos C; Bruhn J; Phinney DG
Exp Hematol; 2010 Oct; 38(10):957-967.e1. PubMed ID: 20600575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
